Triheptanoin (Dojolvi)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses triheptanoin (Dojolvi), 100% w/w oral liquid. Indication: As a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders.